S. J. Lehman

Learn More
Bivalirudin is a member of the direct thrombin inhibitor group of anticoagulants. It has been evaluated as an alternative to unfractionated and low-molecular-weight heparins in the settings of percutaneous coronary intervention (PCI) and acute coronary syndrome (ACS). Results of clinical trials to date suggest bivalirudin is a viable alternative to the use(More)
As manufacturing operations expand or contract with changing economic climates, there is a need to identify alternative office, factory and plant space requirements. These analyses may include the rearranging of office or factory space, the addition of new facilities and equipment, or the contraction and consolidation of existing space. Often, this analysis(More)
  • 1